COX-2-IN-14 (compound 2a) is a highly potent and selective inhibitor of COX-2 (cyclooxygenase-2), with strong binding affinity at the active site of COX-2 co-crystal. Demonstrating remarkable in vivo anti-inflammatory activity, COX-2-IN-14 effectively reduces ear edema and myeloperoxidase (MPO) activity in mice [1].
COX-2-IN-13 (compound 13e) is a highly potent and selective inhibitor of COX-2, demonstrating a remarkable IC50 value of 0.98 μM. It exhibits strong anti-inflammatory activity and has shown favorable results in vivo acute toxicity studies [1].
COX-2-IN-18 (Compound 3) is a highly effective COX-2 inhibitor with strong inhibitory activity against COX-2 (IC 50 = 0.775 μM). Its potency is comparable to the reference drug Celecoxib (IC 50 = 0.153 μM). This compound, COX-2-IN-18, shows promise in the field of cancer research [1].